﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Academy of Medical Sciences of I.R. Iran</PublisherName>
      <JournalTitle>Archives of Iranian Medicine</JournalTitle>
      <Issn>1029-2977</Issn>
      <Volume>18</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2015</Year>
        <Month>03</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Health Status and Quality of Life in Patients with Psoriasis: An Iranian Cross-Sectional Survey</ArticleTitle>
    <FirstPage>0</FirstPage>
    <LastPage>0</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mahshid</FirstName>
        <LastName>Moradi</LastName>
      </Author>
      <Author>
        <FirstName>Fanni</FirstName>
        <LastName>Rencz</LastName>
      </Author>
      <Author>
        <FirstName>Valentin</FirstName>
        <LastName>Brodszky</LastName>
      </Author>
      <Author>
        <FirstName>Ahmad</FirstName>
        <LastName>Moradi</LastName>
      </Author>
      <Author>
        <FirstName>Orsolya</FirstName>
        <LastName>Balogh</LastName>
      </Author>
      <Author>
        <FirstName>László</FirstName>
        <LastName>Gulácsi</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">
      </ArticleId>
    </ArticleIdList>
    <History>
    </History>
    <Abstract> BACKGROUND: Psoriasis has a significant negative impact on patients’ health-related quality of life (HRQOL). This study aims to evaluate HRQOL of adult patients with psoriasis in Iran, and explore the relationship between general and disease-specific outcome measures in psoriasis. METHODS: Between May and August 2013, a cross-sectional questionnaire survey of consecutive outpatients was conducted at a single clinic in Shiraz, Iran. HRQOL was assessed by the general measure EuroQol 5 dimensions (EQ-5D), visual analogue scale (EQ VAS), and the disease-specific Dermatology Life Quality Index (DLQI). Disease severity was measured by the Psoriasis Area and Severity Index (PASI). RESULTS: Sixty-two patients (76% males) completed the questionnaire with a mean age (SD) of 40.4 (17.5) years. Overall, 39% of the patients used only topical and 48% received systemic non-biological therapy in the past 12 months. Median EQ-5D, EQ VAS, DLQI and PASI scores were 0.73, 60, 8 and 11.75, respectively. Out of the 62 patients, 18%, 26%, 28%, 63%, and 63% reported some or severe problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression, respectively. EQ-5D and EQ VAS correlated moderately with DLQI (rs = -0.44 for both, p &lt; 0.001), but only EQ VAS correlated significantly with PASI (rs = -0.31, p &lt; 0.01). CONCLUSION: This is the first study from Iran that assesses HRQOL in adult patients with psoriasis by EQ-5D and EQ VAS. Reduction in general HRQOL measured with EQ-5D and EQ-VAS is considerable, mostly in anxiety/depression and pain/discomfort dimensions. EQ-5D scores evaluated in this study provide country-specific data for economic evaluations. </Abstract>
  </Article>
</ArticleSet>